CoChat
Sign Up
Cited by 42Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Hemoglobin A1c (HbA1c) predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital

Shimazaki, Tamae, Kadowaki, Takashi, Ohyama, Yoshiharu, Ohe, Kazuhiko, Kubota, Kiyoshi·2007·Translational research
DOI 10.1016/j.trsl.2006.09.008
Open this paper in CoChat — free account

Abstract

Hemoglobin A1c (HbA1c) has been widely used as a measure of glycemic control in patients with diabetes mellitus. However, the role of HbA1c in the prediabetic stage has received little attention, although the effectiveness of early intensive intervention for the prediabetic patients defined by plasma glucose is well documented. In this study, routine clinical data in a Japanese university hospital were used to address whether the level of HbA1c predicted drug treatment for diabetes mellitus. The study population consisted of 38,628 adolescent and adult patients (>or=15 years old) who used routine medical care services provided by the hospital and who were prescribed no anti-diabetic drugs in the 12 months before the 3-year study period. The rates of starting anti-diabetic drugs during the study period were calculated for subgroups divided by the level of HbA1c followed by Kaplan-Meier survival analysis and Cox proportional-hazard regression. In addition, the medical records of middle-aged patients with borderline (5.6-6.4%) and high (>or=6.5%) levels of HbA1c were examined to estimate the rates of initial drug treatment for type 2 diabetes mellitus. The rate (95% confidence interval; CI) of beginning anti-diabetic drug therapy was 1.5 (0.9-2.5)/1000 patient-years in patients with a normal level of HbA1c ( or=6.5%) level of HbA1c was found to strongly predict future drug treatment for diabetes mellitus.

Integrity signals

Registry

Crossref · 10.1016/j.trsl.2006.09.008

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • People within the A1C range of 5.5-6.0% have a 5-year cumulative incidence of diabetes that ranges from 12 to 25%.

    “Prospective studies indicate that people within the A1C range of 5.5–6.0% have a 5-year cumulative incidence of diabetes that ranges from 12 to 25% (4–7), which is appreciably (three- to eightfold) higher than incidence in the U.S. population as a whole (8).”

    From Diagnosis and classification of diabetes mellitus (2013) · cites this paper as [7]

  • Incidence of diabetes in people with A1C levels in the 6.0 to <6.5% range is more than 10 times that of people with lower levels.

    “Indeed, incidence of diabetes in people with A1C levels in this range is more than 10 times that of people with lower levels (4–7).”

    From Diagnosis and classification of diabetes mellitus (2013) · cites this paper as [7]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Shimazaki, T., Kadowaki, T., Ohyama, Y., Ohe, K., & Kubota, K.
Affiliations
  • The University of Tokyo (JP)
  • Nihon Pharmaceutical University (JP)
Corresponding author
Kubota, Kiyoshi
ORCID
Venue
Translational research
Publisher
Elsevier BV
Published
2007-04
Volume
149
Issue
4
Pages
196-204
ISSN
  • 1878-1810 (ISSN-L)
  • 1931-5244
DOI
10.1016/j.trsl.2006.09.008
OpenAlex
W1983781114
Cited by
42
References
37
Citations by year
2023: 6 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 3 · 2012: 3
FWCI
1.96
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Translational research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
HbA1c, prediabetes, type 2 diabetes, glycemic control, early intensive intervention, diabetes prevention, risk prediction, Japanese adults, adolescents, middle-aged adults, routine clinical data, hospital medical records, HbA1c thresholds
MeSH terms
Adolescent, Adult, Diabetes Mellitus, Female, Follow-Up Studies, Glycated Hemoglobin, Hospitals, University, Humans, Hypoglycemic Agents, Japan, Male, Middle Aged, Prediabetic State, Predictive Value of Tests, Proportional Hazards Models, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review